Meridian Bioscience Inc

Meridian Bioscience — Q1 FY2021 Earnings Presentation

11 slides from Meridian Bioscience's earnings presentation, Feb 5, 2021

  1. Slide 1: FY2021 Q1 Results

    FY2021 Q1 Results February 5, 2021 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A

  3. Slide 3: Non-GAAP Financial Measures

    Certain financial measures presented in this presentation, such as operating expenses, operating income, operating margin, net earnings and net earnings per diluted share, each on an adjusted basis, excluding as applicable the effects of acquisition-related costs, changes in fair value of acquisitio

  4. Slide 4: Q1 FY2021 Business Highlights

    Record quarter for Meridian in sales and earnings Received RADx grant for development of Revogene® SARS-CoV-2 Assay and submitted for FDA Emergency Use Authorization Launched paradigm-shifting Air-Dryable Master Mix to replace lyophilization in manufacturing of molecular assays Q1 FY2021 Business Hi

  5. Slide 5: First Quarter Earnings Summary

    FY2021 First Quarter Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2021 FY2020 Change Net revenues $92,917 $47,421 +96% Gross margin % 66% 58% +8 pts Operating expenses(1) Ratio $24,610 26% $20,475 43% +20% -17 pts Operating income Margin % $36,938 40% $7,176 15% +415% +25

  6. Slide 6: First Quarter Operating Segment Highlights

    FY2021 First Quarter Operating Segment Highlights ($000’s) Diagnostics segment (Adjusted Non-GAAP) FY2021 FY2020 Change Net revenues $30,321 $34,791 -13% Operating income / (loss) Margin % ($135) NMF $6,458 19% NMF NMF Diagnostics revenue by: Technology: Molecular assays $4,590 $6,903 -34% Non-molec

  7. Slide 7: Fiscal Year Guidance

    FY2021 Fiscal Year Guidance Meridian Bioscience Diagnostics Life Science Prior Guidance Updated FY2021 Guidance Meridian Bioscience Consolidated net revenues: $320 to $350 Million Adjusted operating margin: 31% to 33% Adjusted net earnings per share*: $1.70 to $1.90 Diagnostics Net revenues: $140 to

  8. Slide 8: The Revogene SARS-CoV-2 Assay

    Minimal hands-on time Sample to result in 2 steps with less than 1-minute hands-on time allowing lab techs to improve lab workflow efficiency The Revogene® SARS-CoV-2 Assay Platform for growth First RNA based assay which opens additional opportunities to grow the respiratory franchise Performance yo

  9. Slide 9: How it works: The Air-Dryable Mix Revolution

    How it works The Air-Dryable Mix Revolution What it does? Replaces the need to lyophilize a molecular kit to make it room temperature stable Why is this important? Cost per test drops ($1-3/test) Everyone can do this in house with an oven, very simple Large market opportunity Ideal for price sensiti

  10. Slide 10: Diagnostics R&D Pipeline (as of 12/31/2020)

    Diagnostics R&D Pipeline (as of 12/31/2020) Breath Immunoassay Molecular Blood Chemistry Feasibility Development Clinicals FDA Liver MBT PMA C. difficile Campylobacter Shiga Toxin Streptococcus pneumoniae / Legionella RI Panel GI Panel COVID-19 EUA PediaStat Analyzer Lead Hemoglobin Bilirubin Expect

  11. Slide 11: Contact

    Contact: [email protected]

Meridian Bioscience — Q1 FY2021 Earnings Presentation on 6ix